PT - JOURNAL ARTICLE AU - Henning Jacobsen AU - Monika Strengert AU - Henrike Maaß AU - Mario Alberto Ynga Durand AU - Barbora Kessel AU - Manuela Harries AU - Ulfert Rand AU - Leila Abassi AU - Yeonsu Kim AU - Tatjana Lüddecke AU - Pilar Hernandez AU - Julia Ortmann AU - Jana-Kristin Heise AU - Stefanie Castell AU - Daniela Gornyk AU - Stephan Glöckner AU - Vanessa Melhorn AU - Yvonne Kemmling AU - Berit Lange AU - Alex Dulovic AU - Julia Häring AU - Daniel Junker AU - Nicole Schneiderhan-Marra AU - Markus Hoffmann AU - Stefan Pöhlmann AU - Gérard Krause AU - Luka Cicin-Sain TI - Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations AID - 10.1101/2021.12.21.21267898 DP - 2022 Jan 01 TA - medRxiv PG - 2021.12.21.21267898 4099 - http://medrxiv.org/content/early/2022/01/23/2021.12.21.21267898.short 4100 - http://medrxiv.org/content/early/2022/01/23/2021.12.21.21267898.full AB - SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to vaccine-induced protection. The novel variant of concern (VoC) Omicron (B.1.1.529) has the largest number of amino acid alterations in its Spike protein to date. Thus, it may efficiently escape recognition by neutralizing antibodies, allowing breakthrough infections in convalescent and vaccinated individuals. We analyzed neutralization activity of sera from individuals after vaccination with all mRNA-, vector- or heterologous immunization schemes currently available in Europe by in vitro neutralization assay at peak response towards SARS-CoV-2 B.1, Omicron, Beta and Delta pseudotypes and also provide longitudinal follow-up data from BNT162b2 vaccinees. All vaccines apart from Ad26.CoV2.S showed high levels of responder rates (93-100%) towards SARS-CoV-2 wild-type, but some reductions in neutralizing Beta and Delta VoC pseudotypes. The novel Omicron variant had the biggest impact, both in terms of response rates and neutralization titers. Only mRNA-1273 showed a 100% response rate to Omicron and induced the highest level of neutralizing antibody titers, followed by heterologous prime-boost approaches. Homologous BNT162b2 vaccination or vector-based AZD1222 or Ad26.CoV2.S performed less well with peak responder rates of 33%, 50% and 9%, respectively. However, Omicron responder rates in BNT162b2 recipients were maintained in our six month longitudinal follow-up indicating that individuals with cross-protection against Omicron maintain it over time. Overall, our data strongly argues for urgent booster doses in individuals who were previously vaccinated with BNT162b2, or a vector-based immunization scheme.Competing Interest StatementNSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with the Luminex Corporation. The other authors declare no competing interest.Funding StatementThis work was financially supported by the Initiative and Networking Fund of the Helmholtz Association of German Research Centres through projects Virological and immunological determinants of COVID-19 pathogenesis: lessons to get prepared for future pandemics (KA1-Co-02 COVIPA) to LCS and grant number SO-96 to GK, by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germanys Excellence Strategy EXC 2155 RESIST Project ID 39087428 to LCS, and intramural funds of the Helmholtz Centre for Infection Research. SP was supported by BMBF (01KI2006D, 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK HZI COVID-19) and the German Research Foundation (DFG, PO 716/11-1, PO 716/14-1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Hannover Medical School (9086_BO_S_2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is provided with the manuscript. Additional data is available upon request from the corresponding authors.